STOCK TITAN

Abbott Laboratories (NYSE: ABT) grants shares and stock options to director

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Abbott Laboratories director Nancy McKinstry reported equity awards rather than open-market trades. She received 2,286 restricted stock units that will convert one-for-one into common shares upon separation from service, death, or a change in control under Abbott’s 2026 Incentive Stock Program.

She also received options for 2,305 common shares at an exercise price of $91.86 per share, expiring in 2036. Following these awards, she directly holds 41,010 common shares and 2,305 options.

Positive

  • None.

Negative

  • None.
Insider McKinstry Nancy
Role null
Type Security Shares Price Value
Grant/Award Option (right to buy) 2,305 $0.00 --
Grant/Award Common shares without par value 2,286 $0.00 --
Holdings After Transaction: Option (right to buy) — 2,305 shares (Direct, null); Common shares without par value — 41,010 shares (Direct, null)
Footnotes (1)
  1. Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3.
RSU award 2,286 units Restricted stock units under 2026 Incentive Stock Program
Option grant size 2,305 options Options on common shares granted on 2026-04-24
Option exercise price $91.86 per share Exercise price for 2,305 stock options
Option expiration 2036-04-23 Expiration date of stock option grant
Shares held after award 41,010 shares Total common shares directly held following transactions
Options held after award 2,305 options Total options directly held following transactions
Restricted stock unit financial
"Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Incentive Stock Program financial
"granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program")"
Stock option financial
"Stock option granted under the Program, in a transaction exempt from Section 16"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Section 16 regulatory
"in a transaction exempt from Section 16 under Rule 16b-3"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
Rule 16b-3 regulatory
"exempt from Section 16 under Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McKinstry Nancy

(Last)(First)(Middle)
100 ABBOTT PARK ROAD

(Street)
ABBOTT PARK ILLINOIS 60064

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common shares without par value04/24/2026A2,286(1)A$041,010D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option (right to buy)(2)$91.8604/24/2026A2,30504/24/202604/23/2036Common Shares2,305$02,305D
Explanation of Responses:
1. Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
2. Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3.
/s/ Nancy McKinstry by Jessica H. Paik, Attorney-in-Fact04/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Abbott Laboratories (ABT) director Nancy McKinstry report on this Form 4?

Nancy McKinstry reported receiving equity compensation awards, not open-market trades. She was granted 2,286 restricted stock units and options for 2,305 common shares under Abbott’s 2026 Incentive Stock Program, increasing her direct share and option holdings in the company.

How many Abbott (ABT) shares does Nancy McKinstry hold after these awards?

After these awards, Nancy McKinstry directly holds 41,010 Abbott common shares. In addition, she holds stock options covering 2,305 common shares, giving her both current ownership and potential future ownership through the option grant reported in this filing.

What restricted stock unit (RSU) award did Nancy McKinstry receive from Abbott (ABT)?

She received 2,286 restricted stock units granted under Abbott’s 2026 Incentive Stock Program. Each unit will be paid in one Abbott common share on the earlier of her separation from service, death, or a change in control, aligning director compensation with long-term company performance.

What are the key terms of Nancy McKinstry’s Abbott (ABT) stock option grant?

She was granted options on 2,305 common shares at an exercise price of $91.86 per share. The options were granted under Abbott’s 2026 Incentive Stock Program and will expire in 2036, providing long-dated potential equity upside if exercised in the future.

Were Nancy McKinstry’s Abbott (ABT) equity awards exempt from Section 16 rules?

Yes. The filing notes that the stock option grant was made under Abbott’s 2026 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3, which typically covers board-approved, issuer-granted compensation awards to insiders like directors.